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Background
The rising threat of Plasmodium falciparum resistance to
monotherapies prompted the World Health
Organization (WHO) 2006 guidelines for the treatment
of malaria to recommend that combinations of
antimalarials be used to treat malaria caused by P.
falciparum [1]. Since artemisinin derivatives are the only
class of anti-malarial agents to which resistance outside
the Thai-Cambodia border region has not been reported
in vivo [1], the guidelines specifically recommend the use
of artemisinin-based combination therapy (ACT) [1].
WHO criterion for adequate efficacy of ACT in malaria is
the achievement of an average cure rate of ≥95% in
clinical trials [1].
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Abstract
Current World Health Organization (WHO) guidelines for the treatment of uncomplicated
falciparum malaria recommend the use of artemisinin-based combination therapy (ACT). Artemether/
lumefantrine is an ACT prequalified by the WHO for efficacy, safety and quality, approved by
Swissmedic in December 2008 and recently approved by the USA FDA. Coartem® is a fixed-dose
combination of artemether and lumefantrine. Its two components have different modes of action
that provide synergistic anti-malarial activity.It is indicated for the treatment of infants,children and
adults with acute, uncomplicated infection due to Plasmodium falciparum or mixed infections
including P. falciparum.A formulation with improved palatability has been developed especially for
children (Coartem® Dispersible), which rapidly disperses in a small amount of water for ease of
administration.
The efficacy of the six-dose regimen of artemether/lumefantrine has been confirmed in many
different patient populations around the world, consistently achieving 28-day PCR (polymerase
chain reaction)-corrected cure rates of >95% in the evaluable population, rapidly clearing
parasitaemia and fever, and demonstrating a significant gametocidal effect, even in areas of
widespread parasite resistance to other antimalarials.
Open AccessArtemisinin derivatives have the most potent and rapid
onset of anti-parasitic activity of any anti-malarial drug
available today and are active against all Plasmodium
species that infect humans. Importantly, they allow more
parasite clearance than any other anti-malarial drug
(parasite numbers can be reduced by a factor of 105 per
asexual cycle, compared with 102–103 with other anti-
malarial drugs) [2]. When combined with efficacious
anti-malarials with slower elimination rates, such as
lumefantrine, shorter courses of treatment (three days)
become effective [2].
The combination of artemether (an artemisinin deriva-
tive) and lumefantrine in a 1:6 ratio was the first fixed-
dose ACT to meet the WHO’s prequalification criteria for
efficacy, safety and quality [3]. Artemether/lumefantrine
(AL), as Coartem®, now comprises nearly 75% of the 100
million or so ACT treatments used each year [4].
Coartem® was approved by Swissmedic in 1999 and was
recently approved by the USA FDA [5]. Coartem®
Dispersible was approved by Swissmedic in December
2008. More than 40 malaria-endemic countries in sub-
Saharan Africa have rapidly scaled up malaria prevention
and treatment and now recommend the use of ACT as
first-line treatment for uncomplicated falciparum malaria
[6]. Both artemether and lumefantrine are blood
schizonticides with complementary pharmacokinetics
and dissimilar modes of action, and hence provide
synergistic anti-malarial activity [7]. Artemether is rapidly
eliminated from plasma with a half-life of two to three
hours, whereas lumefantrine is eliminated more slowly
with a half-life of three to six days and provides a high
long-term cure rate after a short treatment course [7]. The
combination thus provides rapid clearance of parasitemia
and most malaria-related symptoms, coupled with
prevention of recrudescence.
AL tablets have been included on the WHO model list of
Essential Medicines since March 2002 and on the first
WHO Model List of Essential Medicines for Children
since October 2007 [8,9].
The six-dose AL regimen is currently the approved
treatment regimen for acute, uncomplicated P. falciparum
malaria in adults and paediatric patients with a body
weight ≥5 kg, irrespective of the immune status of the
patients to P. falciparum and of the local multidrug resis-
tance situation, in the majority of the 83 countries in
Africa, Asia, Europe and Latin America where the drug is
registered.
The objective of this paper is to review the literature
investigating the drug’s clinical efficacy. In this respect, it
is important to note that early clinical studies used a four-
dose AL regimen (two doses per day for two days).
However, because this regimen did not provide optimal
efficacy in some areas, such as Thailand, where multi-drug
resistant P. falciparum malaria is prevalent, it was changed
to its current six-dose format (three-day course: dosing at 0,
8, 24, 36, 48 and 60 hours) in 1997. This article will focus
on data involving the six-dose regimen only. In addition to
the key clinical trials that support the drug’s indication for
the treatment of uncomplicated P. falciparum malaria, over
40 independent trials have produced data supporting the
excellent efficacy of this ACT.
Study design considerations
The active comparators used in the controlled studies
summarized below were the standard therapies for each
country as recommended by the WHO at the time.
Placebo-controlled studies are not practical for ethical
reasons because untreated P. falciparum malaria may
progress rapidly, with a potentially fatal outcome. All
comparative studies were randomized, and double-blind
designs were used where practical.
Efficacy evaluations
The key criterion used to assess the efficacy of an anti-
malarial agent is the elimination of malaria parasites,
which in turn leads to resolution of symptoms such as
fever. Unless otherwise stated, the primary efficacy end-
point in the studies outlined below was the 28-day
parasitological cure rate. This describes the proportion of
patients with clearance of asexual parasitaemia within
seven days of initiating study treatment without recrudes-
cence at day 28, based on blood smears. In most studies,
the 28-day cure rate was also corrected by polymerase
chain reaction (PCR) to differentiate between recurrence
of the initial infection and a new infection. This is
particularly important in highly endemic regions, as is the
case in many parts of sub-Saharan Africa, where re-
infection is common.
Several secondary efficacy endpoints were also evaluated.
These included: 7-day, 14-day, and/or 42-day parasito-
logical cure rates; fever clearance time (FCT) in patients
who had fever at baseline; parasite clearance time (PCT)
and gametocyte clearance time (GCT).
The evaluable population included all patients with
confirmed P. falciparum malaria who received at least one
dose of study drug and had parasite counts performed at
the pre-specified time points, including day 28, or who
discontinued due to unsatisfactory therapeutic effect.
The primary efficacy endpoint was also evaluated in the
modified intent-to-treat (mITT) population, which
included all patients with confirmed P. falciparum malaria
who received at least one dose of study drug. Since
patients who did not have a parasite count performed at
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mITT analysis, the evaluable population analysis gives the
most clinically relevant result as it better reflects the true
activity of the drug (i.e. it avoids classifying as treatment
failure patients who did not have a parasite count
performed but who may have been cured).
Efficacy of AL studied in children and adults
Six key clinical studies, summarized in Table 1 [10–15],
have been conducted to evaluate the efficacy of the six-
dose AL regimen in a range of patient populations and
geographic regions with varying levels of drug resistant P.
falciparum and malaria endemicity. In all studies, patients
were either non-immune or semi-immune to P. falciparum.
Some of the studies included other anti-malarial drugs or
combinations as active comparators and some also
allowed the inclusion of patients with mixed infections
that included P. falciparum at baseline.
Study AO25
This randomized, double-blind study enrolled 359 adults
and children above two years of age with uncomplicated
P. falciparum in two centres in Thailand. It compared the
AL four-dose regimen to two different six-dose regimens,
one administered over 60 hours and one administered
over 96 hours [10].
AL achieved a 28-day PCR-corrected cure rate of 96.9% in
the evaluable population (Figure 1) [10]. All patients
cleared peripheral parasitaemia rapidly – the median
parasite clearance time was 44 hours [10]. Median fever
clearance time was 35 hours, and no patient developed
gametocytaemia following treatment [10].
Since the efficacy was similar between the 96 and 60-hour
six-dose regimens, the 60-hour regimen was chosen for
further development to facilitate better compliance with a
shorter treatment duration.
Studies A026 and A028
These two randomized, open-label studies were both
conducted in Thailand and included mefloquine plus
artesunate (MAS) as an active control arm [11,12].
Study 026 enrolled patients ≥2 years of age [11], and
Study 028 enrolled patients >12 years of age [12]. The
open-label design for both studies was chosen because of
the excessive number of placebo tablets (24) patients
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Table 1 – Clinical studies evaluating the efficacy and safety of the six-dose regimen of artemether/lumefantrine
Study number A025 [10] A026[11] A028[12] A2403[13] B2303[14] A2401[15]
Design Randomized Randomized Randomized Open-label Randomized Open-label
double-blind open-label open-label investigator blind
Comparator Four-dose MASa  MASa – Dispersible –
regimen formulation
Patients Adults &  Adults &  Adults &  Infants &  Infants &  Adult 
children children adolescents children children non-immune  travellers
(>2 years) (≥2 years) (>12 years) (5 to 25 kg) (5 to <35 kg)
N AL/ total 120/359b 150/200 164/219 310 452/899 165
Geography Thailand Thailand Thailand Kenya Kenya EU 
Tanzania Tanzania Colombia
Nigeria Mali 
Benin 
Mozambique
28-day PCR-  96.9% 97.7% 95.5% 96.7% 97.8%  96.0%
corrected 
cure rate 
(evaluable pts)
Median time  35 (n=59) 22 (n=87) 29 (n=76) 7.8 (n=309) 7.8 (n=311) 36.5 (n=100)
to fever 
clearance (h) 
(mITT popn)
Median time  43.6 (n=118) 48 (n=149) 29.3 (n=164) 24.0 (n=310) 34.9 (n=452) 41.8 (n=162)
to parasite 
clearance (h) 
(mITT popn)
aStudy was not designed to compare AL with mefloquine + artesunate; bAL over 60 hours; c28-day cure rate was a secondary endpoint.Abbreviations:
AL, artemether/lumefantrine; MAS, mefloquine + artesunate.would have had to take if a double-blind/double-dummy
design had been used.
In Study 026, 150 patients received AL and 50 patients
received mefloquine and artesunate. Patient charac-
teristics were comparable between treatment groups, and
treatment comparisons were not affected by a difference
in baseline parasite density. The 28-day PCR-corrected
cure rates were >95% in the evaluable population for
both treatment groups (Figure 1). The median fever and
parasite clearance times were identical in the two
treatment groups [11].
In Study 028, 164 patients received AL and 55 patients
received MAS. Patient characteristics were similar to those
seen in Study 026 and were comparable across treatment
groups, except for parasite density which was slightly
lower than in Study 026 [11,12].
Once again, the 28-day cure rates were >95% in the evalu-
able population and were comparable in both treatment
groups (Figure 1). The lower boundary of the confidence
interval was greater than 85%. Median fever and parasite
clearance times were in the range of 20 to 30 hours in
both groups [11,12].
Study A2403
This was an open-label non-comparative study performed
in collaboration with the WHO. It was designed to
examine the safety and efficacy of AL in 310 infants and
young children (5–25 kg body weight) in sub-Saharan
Africa (Kenya, Nigeria, and Tanzania) [13]. In the absence
of an ethical comparator agent for paediatric patients with
a body weight of 5 to <10 kg at the time of the study, it
was a single-arm study. The median age was 24 months,
ranging from two months to 10 years. AL tablets were
crushed and mixed with sterile water to facilitate
administration to those children who were unable to
swallow whole tablets [13]. In all cases, treatment was
given after feeding.
The overall 28-day cure rate, corrected for reinfection, was
93.9% for the intent-to-treat population [13]. The median
time to parasite clearance ranged from 24 to 36 hours,
with 98.4% of patients achieving parasite clearance
within 48 hours of their first dose [13]. The median time
to fever clearance was less than eight hours [13], and none
of the children had gametocytes after day 14 [13].
Study B2303
To facilitate administration of AL to children, a sweet-
tasting dispersible formulation has been developed. The
primary objective of Study B2303, which enrolled 899
African children (5–<35 kg body weight), was to demon-
strate non-inferiority of the dispersible tablet to the
crushed tablet based on the 28-day PCR-corrected cure rate
in the evaluable population. The median age of children
enrolled was 36 months, ranging from two months to
12 years, and the median body weight was 13 kg [14].
In the evaluable population, the 28-day PCR-corrected
cure rate for the group receiving crushed tablets was
98.5%, compared with 97.8% for the group receiving the
dispersible formulation of AL (Coartem® Dispersible)
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Figure 2
Efficacy of dispersible AL formulation across body weight
groups [14].
Figure 1
28-day PCR-corrected cure rate for artemether/
lumefantrine in Studies A025,A026 and A028 [10–12].[14]. The PCR-adjusted cure rates for the two groups were
also comparable at day 14 and day 42 [14]. Notably, the
cure rates were comparable across body weight groups
(Figure 2) [14]. In addition, there were no significant
differences between those receiving the dispersible
formulation and those receiving crushed tablets with
regard to median time to parasite clearance (Figure 3A)
and median time to fever clearance (Figure 3B) [14].
Study A2401
This study was designed to assess the efficacy of AL in
non-immune populations (e.g. travellers). To date, it is
the largest study investigating a drug for the treatment of
malaria in travellers. Because of practical considerations
related to the availability of patients, it was an open-label,
single-arm study. A total of 165 patients who had been
diagnosed with non-endemic malaria were enrolled from
Europe and non-malarious areas of Colombia. Non-
immune patients were defined as those who had not
spent the first five years of their life, nor the five years
prior to study entry, in a malaria-endemic area, and had
not had acute P. falciparum malaria diagnosed during the
past 5 years.
A high 28-day cure rate of 96% (both uncorrected and
PCR-corrected) was observed in the evaluable population
(Figure 4) [15]. The median time to parasite clearance was
41.5 hours and the median time to fever clearance was
36.8 hours [15].
A total of 599 adult patients (>16 years) and 877 children
(<16 years) were treated with the six-dose AL regimen in
the above studies. The 28-day PCR-corrected cure rate in
evaluable patients consistently met WHO criteria for
efficacy (>95%) in both adults and children. Rapid
clearance of parasitaemia and fever was also evident,
although noticeably quicker in children.
Comparative results from independent studies
A large number of independent studies have compared
the efficacy of AL with other anti-malarial treatments.
These studies conclusively show that AL is highly
efficacious and at least as effective as other ACTs and
combinations of antimalarials over a wide range of
geographical areas and in a variety of populations. A
summary of these trials is presented in Tables 2 and 3.
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Figure 4
28-day PCR-corrected cure rate for AL in Study A2401 [15].
Figure 3
Median time to (A) parasite clearance and (B) fever clearance for dispersible artemether/lumefantrine formulation and
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Table 2 – Published studies with the six-dose AL regimen in Africa 
Design and patient  Comparator(s) 
Authors Country population No. of patients Results
Bukirwa  Uganda Randomized, single- AL (n=208)  Primary efficacy outcome was the 28-day risk of recurrent symptomatic malaria 
et al 2006  blind, single centre in  ASAQ (n=211) (AL=27%;ASAQ=42%) and recurrent parasitaemia (AL=51%;ASAQ=66%) both 
[16] children (1–10 years) unadjusted for re-infection (both p=0.001).When corrected for re-infection using 
PCR, the risks for both recurrent symptomatic malaria and parasitaemia were 0% 
for ASAQ and 1% for AL (equivalent to PCR-adjusted 28-day parasitological cure 
rates of 100% and 99%, respectively), illustrating the high rate of re-infection in the 
area studied.
Dorsey  Uganda Single-blind, AL (n=105)  PCR-corrected 28-day cure rates of 99% with AL, 95.4% with ASAQ and 85.9% 
et al 2007 randomized, single  AQSP (n=111)  with AQSP.The differences between AL and AQSP, and between ASAQ and AQSP 
[17] centre in children  ASAQ (n=113) were statistically significant (p<0.001 and p=0.08, respectively).
(1–10 years) Clearance of fever, sexual parasites and gametocytes were similar in the AL and 
ASAQ groups but slower in the AQSP group.
Gürkov  Ethiopia One centre, AL (n=30)  At 28-days, there were no treatment failures in the AL group, but the PCR-
et al 2008  comparative in adults  Quinine (n= 5)  confirmed recrudescence rates in the quinine and atovaquone/proguanil groups 
[18] and children >5 years  Atovaquone/ were 9% and 6%, respectively.
of age Proguanil (n=32)
Kabanywanyi Tanzania Randomized, open- AL (n=99)  28-day PCR-corrected rates of adequate clinical and parasitological response were 
et al 2007  label, 2-centre in  ASAQ (n=76) 100% for AL and 93.8% for ASAQ. Late parasitological failures, in all cases due to 
[19] children (6–59 months) re-infection rather than recrudescence, occurred in 12% and 29% of each group,
respectively.
Kamya  Uganda Single-blind, AL (n=210)  PCR-corrected risk of recurrent parasitaemia at Day 28 was significantly lower 
et al 2007  randomized, single  DP (n=211) with DP than with AL (1.9% vs. 8.9%); this was also the case at Day 42 (6.9% vs.
[20] centre in children  16%). However, due to the complexity of infection in this area of very high 
(6 months to 10 years) transmission, leading to difficulty in distinguishing between new and recrudescent 
infections, the risks of recrudescence are probably overstated.
Times to clearance of fever and parasites were similar in the two treatment 
groups, although DP was associated with better control of gametocytes.
Mårtensson  Zanzibar Multicenter, AL (n=200)  PCR-corrected 28-day and 42-day parasitological cure rates of 97% and 92%,
et al 2005  randomized, open- ASAQ (n=208) respectively, for AL and 91% and 88%, respectively, for ASAQ (p=0.001 at 28 days 
[21] label in children  and p=0.045 at 42 days).
(6–59 months) Parasite and fever clearance were rapid with both treatments, and gametocyte 
carriage was low in both groups.
Mårtensson  Tanzania Randomized, single  AL (n=50)  PCR-corrected 42-day parasitological cure rates were 98% or 94% in the AL 
et al 2007  centre, open-label  SP (n=56) group (depending on whether standard or enhanced PCR was used);
[22] study in children  corresponding figures in the SP group were 70% and 66%, respectively.
Mohamed  Sudan 2-centre, open-label, AL (n=72)  In this area of low malaria transmission both AL and ASSP were associated with 
et al 2006  treatment assigned  ASSP (n=71) adequate clinical and parasitological response rates of 100% at Day 28.
[23] by centre, in children 
and adults
Mukhtar  Sudan Randomized, single  AL (n=80)  PCR-corrected rates of adequate clinical and parasitological response of 93.4% for 
et al 2007  centre, open-label  ASSP (n=77) ASSP and 91.3% for AL.The treatment regimen used was not clear.
[24] study in children & 
adults
Mutabingwa  Tanzania Randomized, single  AL (n=519)  PCR-corrected 28-day parasitological cure rates were 51.6% for AQ, 65.5% for 
et al 2005 centre, open-label  ASAQ (n=515)  AQSP, 88.8% for ASAQ, and 97.2% for AL.
[25]  study in children AQSP (n=507)  Recruitment to the AQ group was stopped early by the trial’s data and safety 
AQ (n=270) monitoring board due to a high treatment failure rate.
Yeka  Uganda Randomized, one  AL (n=227)  At 42 days there was no statistically significant difference in the risk of 
et al 2008  centre, single-blinded, DP (n=234) recrudescence (5.8% for AL vs. 2.0% for DP; risk difference = 3.8%, 95% CI 
[26] in children aged  0.2–7.8%), although recurrent parasitaemia (uncorrected for re-infection) was 
6 months to 10 years more frequent with AL (33.2% vs. 12.2% for DP).
Mulenga  Zambia Randomized, open- AL (n=485)  AL was associated with significantly faster clearance of fever, parasitaemia and 
et al 2006  label, multicentre, SP (n=486) gametocytes than SP, and a higher Day 45 PCR-corrected cure rate (94.6% vs.
[27] in adults 80.7%, p<0.001).
Toovey  Mozam- Non-comparative, AL (n=54) 28-day parasitological cure rate of 100%.
2008 [28] bique open-label, single 
centre in adults
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Table 2 – Continued
Design and patient  Comparator(s) 
Authors Country population No. of patients Results
Adjei  Ghana Randomized, open  AL (n=111)  For the AL group, adequate clinical and parasitological response was reported in 
et al 2008  label AS+AQ (n=116) 97.1% patients at Day 14 and 94.2% at Day 28; corresponding figures for ASAQ 
[29] were 98.2% and 95.3%.
Falade  Nigeria Randomized, open  AL (n=66)  PCR-corrected 28-day parasitological cure rates of 100% for AL and 98.4% for 
et al 2008  label, single centre in  ASAQ (n=66) ASAQ.
[30] children (6 months 
to 10 years)
Faye  Senegal Randomized, open- ASAQ (n=360)  PCR-corrected 28-day parasitological cure rates were 100% for all treatments 
et al 2007  label, multicentre in  AQSP (n=161)  other than AL four-dose (96.4%). Parasite clearance was observed to be more 
[31] children and adults MAS (n=145)  rapid with all ACTs than with AQSP.
AL (6 dose)  Initial reduction of gametocyte carriage also appeared to be more rapid with the 
(n=149)  ACTs than with AQSP, although all patients were free of gametocytes by day 21.
AL (four-dose) 
(n=140)
Koram  Ghana Multicentre, AL (n=51)  PCR-corrected 28-day cure rates of 25% for chloroquine, 60% for SP, 100% for 
et al 2005  randomized, open- CQ (n=36)  ASAQ, and 97.5% for AL.
[32] label in children  SP (n=27) 
(6–59 months) ASAQ (n=54)
Meremikwu  Nigeria Randomized, open- AL (n=60)  Both treatments highly effective with similar rates of adequate clinical and 
et al 2006  label, single centre, ASAQ (n=59) parasitological response, early treatment failure, late clinical failure and late 
[33] in children  parasitological failure at 14 days.
(6–59 months)
Owusi-Agyei  Ghana Randomized, open  AL (n=223)  Per-protocol analysis showed a lower PCR-corrected parasitological and clinical 
et al 2008  label in children aged  ASAQ (n=220)  failure rate at day 28 in the ASAQ group (6.6%) compared with the AL group 
[34] 6 months to 10 years ASCD (n=178) (13.8%) or ASCD group (13.8%).
Sagara  Mali Randomized, single  AL (n=303)  28-day PCR-corrected parasitological cure rates were 100% for AS plus 
et al 2006  centre, open-label  AS plus  sulphamethoxypyrazine plus pyrimethamine, and 99% for AL.
[35] study in children  sulphamethoxy- Gametocyte clearance was similar in the two treatment groups.
(≥6 months) and  pyrazine plus 
adults pyrimethamine 
(n=303)
Sowunmi  Nigeria Randomized, open- AL (n=90)  PCR-corrected parasitological cure rates at 42 days were 93.3% for AL and 98.9% 
et al 2007  label, single centre, AQ plus  for AQ plus sulphalene plus pyrimethamine.
[36] in children (≤10 years) sulphalene plus 
pyrimethamine 
(n=91)
Sutherland  Gambia Randomized, single  AL (n=406)  PCR-corrected 28-day cure rates were 96.1% for AL and 91.1% for CQSP.
et al 2005  centre, single-blind, CQSP (n=91) AL-treated patients were statistically significantly less likely to carry gametocytes 
[37] in children (1–10 years)  at Day 28 than those who received CQSP (8% vs. 49%, p<0.0001), and carriers in 
the AL group harboured gametocytes at lower densities, for shorter periods 
(0.3 d vs. 4.2 d, p<0.0001) and were less infectious to mosquitoes at day 7 
(p<0.001) than carriers in the CQSP group.
Zongo  Burkina  Multicentre, AL (n=261)  The crude (uncorrected for re-infection) risk of recurrent malaria at 28 days was 
et al 2007  Faso randomized, open- AQSP (n=260) significantly higher with AL than AQSP (10.2% vs. 1.7%, p<0.0001); PCR correction 
[38] label in children  gave risks of recurrent malaria of 1.2% and 0.4%, with the between-group 
(6 months to 10 years) difference not statistically significant.
Zongo  Burkina  Multicentre, AL (n=188)  PCR-corrected risks of re-infection at Day 28 were AL, 3.4%; DP, 2.2% and AQSP,
et al 2007  Faso randomized, open- AQSP (n=184)  3.9%.
[39] label in children  DP (n=187)
(≥6 months)
Fanello  Rwanda Randomized, open- AL (n=251)  AL was associated with a statistically significantly higher rate of PCR-adjusted 
et al 2007  label, 2-centre in  AQSP (n=249) adequate clinical and parasitological response at Day 28 than AQSP (96.8% vs.
[40] children 79.4%, p<0.0001).
(12–59 months) Gametocyte carriage was significantly lower in the AL group at all post-baseline 
time points.
Guthman  Angola Randomized, open- AL (n=61) PCR-corrected 28-day parasitological cure rates were 100% for both AL and 
et al 2006  label, single centre in  ASAQ (n=64) ASAQ.
[41] children (6–59 months)
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Table 2 – Continued
Design and patient  Comparator(s) 
Authors Country population No. of patients Results
Ndayiragije  Burundi Multicentre, AL (n=142)  14-day rates of adequate clinical and parasitological response were similar 
et al 2004  randomized, open- ASAQ (n=153) between treatment groups:AL=99.3%;ASAQ=95.3%.
[42] label in children  Effects on gametocyte carriage were also similar between treatments.
(<5 years)
van den  Republic  Randomized, single  AL (n=106)  PCR-corrected 28-day parasitological cure rates were 100% for AL, 98.5% for 
Broek et al  of Congo centre, open-label  ASAQ (n=101)  ASAQ and 90.1% for ASSP.The differences in cure rates between AL and ASSP, and 
2006 [43] study in children  ASSP (n=91) between ASAQ and ASSP, were statistically significant.
(6–59 months) Clearance of asexual parasites, gametocytes and fever were rapid in all three 
treatment groups.
AL:Artemether/lumefantrine; CQ: Chloroquine; SP: Sulphadoxine plus pyrimethamine; CQSP: Chloroquine plus sulphadoxine plus pyrimethamine;AS:
Artesunate;AQ:Amodiaquine;ASAQ:Amodiaquine plus artesunate;AQSP:Amodiaquine plus sulphadoxine-pyrimethamine; DP: dihydroartemisinin plus
piperaquine; MAS: mefloquine plus artesunate
Table 3 - Published studies with the six-dose artemether/lumefantrine regimen in Asia
Design and patient  Comparator(s) 
Authors Country population No. of patients Results
South-East Asia
Krudsood  Thailand Randomized, open-label, single  AL (n=41)  The 28-day parasitological cure rates (not PCR corrected) were 
et al 2003 [45] centre in adults DNP (n=89) 99% for DNP and 97% for AL.
Rojanawatsirivej  Thailand Open-label, multicentre, adults  AL (n=33)  All 33 (100%) patients treated with AL plus primaquine had 
et al 2003 [46] & children (10–74 years), MAS (n=199)  adequate clinical response (i.e. parasitological cure at Day 28),
treatment by area (all treatment  Mefloquine  compared with 86.3% of the 80 patients who received mefloquine 
groups also received primaquine) (n=318) plus primaquine.
Stohrer et al  Laos Randomized, open-label, single  AL (n=53)  PCR-corrected cure rates at Day 42 were 93.6% for AL and 100% 
2004 [47] centre, in adults & children  MAS (n=55) for MAS.The difference between treatment groups was not 
(≥10 kg) statistically significant. Day 28 cure rates were identical to those 
at Day 42.
Mayxay et al  Laos Randomized, open-label, single  AL (n=110)  42-day PCR-corrected parasitological cure rates were 97% for AL,
2004 [48] centre, in adolescents and adults  MAS (n=110)  100% for MAS and 93% for CQSP.The difference in cure rates 
(12–19 years) CQSP (n=110) between MAS and CQSP was statistically significant.
Ratcliff et al  Indonesia Randomized, open-label, 2-centre  AL (n=387)  For P. falciparum infections, rates of recrudescence at 42 days 
2007 [49] in children (body weight ≥10 kg)  DP (n=387) (PCR-corrected) were 4.7% with AL and 4.1% with DP.
and adults with P. falciparum,
P. vivax, or mixed infections
Hutagalung  Thailand Randomized, open-label, 2-centre, AL (n=245)  Both treatments were associated with rapid clearance of fever 
2005 [50] in children (>10 kg) and adults MAS (n=245) and parasitaemia. 42-day parasitological cure rates were 98.8% for 
AL and 96.3% for MAS.
South Asia
van den  Bangladesh Randomized, open-label, single  AL (n=121)  Day 42 PCR-corrected cure rates were 62.4% for CQSP, 100% 
Broek et al  centre, in adults & children  MAS (n=121)  for MAS and 97.1% for AL.The cure rate in the CQSP group was 
2005 [51] (≥1 year) CQSP (n=122) statistically significantly lower than that in the other treatment 
groups.
Haque et al  Bangladesh Open-label, non-comparative, AL (n=67) Rapid fever and parasite clearance, and PCR-corrected 28- and 
2007 [52] 2-centre in adults (≥18 years) 42- day parasitological cure rates of 98.3% and 94.3%, respectively.
Thapa et al  Nepal Randomized, open-label, single  AL (n=66)  The 28-day PCR-corrected parasitological cure rate for AL was 
2007 [53] centre, in adults & children  SP (n=33) 100%, compared with 87.9% in the SP group (p=0.011).
(>5 years)
1Includes 2 MAS regimens (mefloquine at 25 mg/kg, n=153, and 15 mg/kg, n=46);AL: artemether/lumefantrine; SP: sulphadoxine plus pyrimethamine;
CQSP: Chloroquine plus sulphadoxine pyrimethamine; DP: Dihydroartemisinin plus piperaquine; DNP: dihydroartemisinin, napthoquine and trimethoprim;
MAS: mefloquine plus artesunateStudies in Africa
In studies reported from Africa, summarized in Table 2
[16–43], the six-dose AL regimen appeared to be at least
as effective as most other forms of ACT included in
comparative studies and was generally more effective than
other, non-ACT, comparators. In the few studies where
comparators were associated with lower risks of treatment
failure than AL, the studies were typically conducted in
areas with very intense malaria transmission, and the
comparators included anti-malarials with a long half-life,
which could prevent re-infection late in the study. Indeed,
the lower crude failure rates with the comparators in these
few studies are the result of lower re-infection rates –
recrudescence rates were generally similar for AL and
comparators.
Several of the publications report the potent effects of
ACT treatment on gametocyte carriage. One study investi-
gated gametocyte carriage in detail and it was found that
in AL-treated patients, not only was the rate of carriage of
gametocytes significantly reduced as compared with that
in patients receiving CQSP, but the carriage time of
gametocytes and the infectivity of the gametocytes for
mosquitoes were also significantly decreased [37]. These
findings potentially have considerable implications for
public health, given the possibility of reducing
transmission of malaria by extensive use of ACT.
Supervised vs unsupervised AL in acute, uncomplicated
falciparum malaria
Piola et al [44] conducted a randomized trial to compare
the efficacy, safety, and pharmacokinetics of AL when
given in a supervised (all doses observed with fatty food
intake; n=313) or unsupervised (first dose supervised
followed by outpatient treatment with nutritional advice;
n=644) setting to patients of all ages (weight >10 kg) with
acute, uncomplicated falciparum malaria in Mbarara,
Uganda. The primary endpoint was 28-day, PCR-adjusted,
parasitological cure rate.
28-day cure rates were very similar (100% in both groups
in an evaluable patient analysis). The only difference
between supervised and unsupervised treatment was that
blood lumefantrine levels in the unsupervised patients
were statistically significantly lower (p<0.001) at Days 3
and 7.
Studies in Asia
The studies reported from South-East Asia, summarized
in Table 3 [45–53], show that in general AL is associated
with similar efficacy to other forms of ACT in the
treatment of P. falciparum malaria, with high parasito-
logical cure rates and rapid clearance of parasitaemia and
resolution of fever. In one study in which P. vivax
infections were included, the comparator ACT (DP) was
significantly more effective in terms of reducing the risk of
recurrent P. vivax infection, probably due to the long half-
life of piperaquine offering protection against re-infection
for longer than lumefantrine: in the same study, PCR-
corrected  P. falciparum parasitological cure rates were
almost identical for AL and DP [50].
Studies from South Asia show high parasitological cure
rates and rapid clearance of fever and parasitaemia with
the six-dose AL regimen, comparable with those for MAS
in the one study where this combination was used as a
comparator. AL was more effective than non-ACT
comparators in these studies.
Meta-analysis
A meta-analysis of 32 published randomized studies per-
formed predominantly in Africa but also in South
America and Asia has evaluated the efficacy of a number
of different forms of ACT using a Bayesian random effects
approach. The analysis showed that AL was one of the
most effective ACT with a 28-day PCR-corrected
parasitological cure rate of 97.4% (Table 4) [54].
Safety and tolerability of
artemether/lumefantrine
The safety and tolerability of AL has been confirmed in
both adults and children in several studies [10–15]. These
data support the use of a six-dose regimen of AL as a safe
and well-tolerated treatment in a wide range of patient
populations including children.
Safety and tolerability are covered in detail in a
companion article in this supplement [55].
Conclusions
Artemether/lumefantrine has consistently met the WHO
criteria for efficacy (>95%) in both adults and children in
randomized, controlled trials in malaria-endemic regions
[10–15]. Efficacy appeared to be maintained across
different populations and regions (Tables 2 and 3); it was
unaffected by bodyweight in infants and children and was
comparable for dispersible and crushed tablets of AL [14].
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Table 4 – Results of a meta-analysis comparing the efficacy of several
anti-malarial combinations [54]
28-day 
PCR-corrected 
Treatment combination cure rate (%)
Artemether/lumefantrine (AL) 97.4
Mefloquine + artesunate (MAS) 96.9
Amodiaquine + artesunate (ASAQ) 88.5
Amodiaquine + sulphadoxine-pyrimethamine (AQSP) 85.7
Sulphadoxine-pyrimethamine + artesunate 82.6
Chloroquine+ sulphadoxine-pyrimethamine (CQSP) 72.1
Chloroquine + artesunate 45.3Effectiveness studies comparing supervised and unsuper-
vised treatment [44] also demonstrated comparable
efficacy data. The 28-day uncorrected cure rate in the per
protocol population was also >95% in non-immune
adult travellers with P. falciparum malaria [15].
A large number of independent studies show the six-dose
AL regimen is at least as effective as other artemisinin-
based combination therapies and combinations of anti-
malarials. A meta-analysis of 32 comparative trials showed
AL to be one of the most effective ACTs currently available
[54].
The combination of artemether and lumefantrine also has
good gametocidal properties, which may help to limit the
spread of resistance [10,12].To date, no resistance toAL in
vivo has been reported in Africa [1].
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